Menu
Search
|

Menu

Close
X

Cue Biopharma Inc CUE.OQ (NASDAQ Stock Exchange Capital Market)

15.00 USD
-0.02 (-0.13%)
As of 9:29 AM EST
chart
Previous Close 15.02
Open 15.00
Volume 1,097
3m Avg Volume --
Today’s High 15.00
Today’s Low 15.00
52 Week High 16.10
52 Week Low 11.10
Shares Outstanding (mil) 16.64
Market Capitalization (mil) 249.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
EPS (USD)
FY17
-0.302
FY16
-0.292
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
--
8.08
Price to Book (MRQ)
vs sector
57.06
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
--
13.67
Return on Equity (TTM)
vs sector
--
15.40

EXECUTIVE LEADERSHIP

Daniel Passeri
President, Chief Executive Officer, Since
Salary: --
Bonus: --
Rodolfo Chaparro
Executive Vice President - Head of Immunology, Since
Salary: --
Bonus: --
Ronald Seidel
Executive Vice President - Head of Research and Development, Since
Salary: --
Bonus: --
Colin Sandercock
Senior Vice President, General Counsel, Since 2017
Salary: --
Bonus: --
Mary Simcox
Vice President - Translational Biology, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

675 W Kendall St
CAMBRIDGE   MA   02142-1110

Phone: +1617.9492680

Cue Biopharma Inc is a United States-based development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

SPONSORED STORIES